在行业变局中稳健前行，睿昂基因2024年年报彰显业绩韧性

Core Viewpoint - In a challenging environment for the in vitro diagnostics industry, Ruian Gene (688217.SH) has demonstrated resilience and forward-looking strategies in its annual performance report for 2024, achieving a revenue of 242 million yuan and a significant focus on R&D investment [2][6]. Financial Performance - The company reported a total revenue of 242 million yuan, with its key product, the lymphoma rearrangement reagent kit, generating 36.66 million yuan, reflecting a year-on-year increase of 12.55% [2]. - R&D expenditure reached 62.47 million yuan, accounting for 25.78% of total revenue, indicating a strong commitment to innovation [2]. - Despite a net profit loss of 15.76 million yuan, the company reported a net cash flow from operating activities of 59.98 million yuan, a year-on-year growth of 33% [2]. Business Focus and Product Development - Ruian Gene specializes in the development, production, and sales of in vitro diagnostic products, focusing on blood diseases, solid tumors, and infectious diseases [3]. - The company achieved revenues of 205 million yuan from self-produced reagents, 20.65 million yuan from testing services, and 4.61 million yuan from research services [3]. - Significant breakthroughs were made in high-end molecular diagnostic products, including the BCR-ABL P210 fusion gene testing kit, which received regulatory approval and filled a gap in leukemia monitoring [3]. - A collaboration with Ruijin Hospital led to the development of a molecular typing kit for diffuse large B-cell lymphoma, improving patient outcomes significantly [3]. Technological Advancements - The company has made notable progress in digitalization and AI applications, particularly in hematological oncology, leveraging extensive bioinformatics data to develop prognostic models for various blood cancers [4]. - Ruian Gene has established an automated laboratory capable of processing 20,000 tests daily, enhancing efficiency and clinical response times [5]. Intellectual Property and Innovation - As of the end of 2024, the company holds 58 patents, including 50 invention patents, and has applied for 8 new patents during the reporting period [5]. - The focus on high-quality monitoring data supports future research and intellectual property strategies [5]. Market Outlook and Strategic Initiatives - The in vitro diagnostics market is projected to reach 22.8 billion yuan by 2026, with a compound annual growth rate of 30.6% from 2026 to 2030, indicating a rapidly growing sector [6]. - The company plans to enhance its marketing system and attract high-end talent to maintain its competitive edge in niche markets [6]. - A share buyback plan has been initiated to support employee stock ownership and incentivize staff, with 669,621 shares repurchased, representing 1.20% of total shares [7]. Future Plans - Looking ahead to 2025, the company aims to focus on R&D, market expansion, and governance upgrades, with a commitment to advancing molecular diagnostic technologies and AI innovations [8].